FG

Grant of unrestricted common stock in lieu of cash director fees.

Grant of unrestricted common stock in lieu of cash director fees.

Grant of unrestricted common stock in lieu of cash director fees.

Grant of unrestricted common stock in lieu of director fees.

Grant of unrestricted common stock in lieu of cash director fees.

Grant of unrestricted common stock in lieu of director fees.

Reflects purchases under the Company's ESPP plan which are not required to be reported on an ongoing basis. The purchases are being reported on this Form 4 to accurately reflect the reporting person's ownership of the issuer's shares as of the current date.

This transaction was executed in multiple trades at prices ranging from $20.975 to $20.989. The price represents a weighted average price of the shares. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the shares purchased at each price.

This transaction was executed in multiple trades at prices ranging from $20.96 to $21.02. The price represents a weighted average price of the shares. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the shares purchased at each price.

Amount reflects purchases under the Company's ESPP plan which are not required to be reported on an ongoing basis. The purchases are being reported on this Form 4 to accurately reflect the reporting person's ownership of the issuer's shares as of the current date.

Amount reflects purchases under the Company's ESPP plan which are not required to be reported on an ongoing basis. The purchases are being reported on this Form 4 to accurately reflect the reporting person's ownership of the issuer's shares as of the current date.

Amount reflects purchases under the Company's ESPP plan which are not required to be reported on an ongoing basis. The purchases are being reported on this Form 4 to accurately reflect the reporting person's ownership of the issuer's shares as of the current date.

Grant of unrestricted common stock in lieu of cash director fees.

Grant of unrestricted common stock in lieu of cash director fees.

Grant of unrestricted common stock in lieu of cash director fees.

This transaction was executed in multiple trades at prices ranging from $29.56 to $29.569. The price represents a weighted average price of the shares. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the shares purchased at each price.

Amount reflects purchases under the Company's ESPP plan which are not required to be reported on an ongoing basis. The purchases are being reported on this Form 4 to accurately reflect the reporting person's ownership of the issuer's shares as of the current date.

On November 7, 2025, Fidelity National Financial, Inc. ("FNF") announced that its Board of Directors had approved a special stock dividend of 16,280,204 shares of common stock, par value $0.001 per share, of F&G Annuities & Life, Inc. owned by FNF to FNF stockholders of record as of 4:30 p.m. ET on December 17, 2025. The distribution of the special stock dividend was made on December 31, 2025.

Distribution of shares obtained from Fidelity National Financial, Inc. spinoff of F&G Annuities & Life, Inc. common stock.

Distribution of shares obtained from Fidelity National Financial, Inc. spinoff of F&G Annuities & Life, Inc. common stock.

Distribution of shares obtained from Fidelity National Financial, Inc. spinoff of F&G Annuities & Life, Inc. common stock.

Distribution of shares obtained from Fidelity National Financial, Inc. spinoff of F&G Annuities & Life, Inc. common stock.

Amount reflects purchases under the Company's ESPP plan which are not required to be reported on an ongoing basis. The purchases are being reported on this Form 4 to accurately reflect the reporting person's ownership of the issuer's shares as of the current date.

Amount reflects purchases under the Company's ESPP plan which are not required to be reported on an ongoing basis. The purchases are being reported on this Form 4 to accurately reflect the reporting person's ownership of the issuer's shares as of the current date.

Amount reflects purchases under the Company's ESPP plan which are not required to be reported on an ongoing basis. The purchases are being reported on this Form 4 to accurately reflect the reporting person's ownership of the issuer's shares as of the current date.

Grant of restricted common stock vesting in three equal annual installments beginning November 10, 2026, subject to the achievement of performance criteria specified in the reporting person's award agreement.

Grant of restricted common stock vesting in three equal annual installments beginning November 10, 2026, subject to the achievement of performance criteria specified in the reporting person's award agreement.

Grant of restricted common stock vesting in three equal annual installments beginning November 10, 2026, subject to the achievement of performance criteria specified in the reporting person's award agreement.

Reflects purchases under the Company's ESPP plan which are not required to be reported on an ongoing basis. The purchases are being reported on this Form 4 to accurately reflect the reporting person's ownership of the issuer's shares as of the current date.

Grant of restricted common stock vesting in three equal annual installments beginning November 10, 2026.

Grant of restricted common stock vesting in three equal annual installments beginning November 10, 2026.

Grant of restricted common stock vesting in three equal annual installments beginning November 10, 2026.

Grant of restricted common stock vesting in three equal annual installments beginning November 10, 2026.

Grant of restricted common stock vesting in three equal annual installments beginning November 10, 2026, subject to the achievement of performance criteria specified in the reporting person's award agreement.

Reflects purchases under the Company's ESPP plan which are not required to be reported on an ongoing basis. The purchases are being reported on this Form 4 to accurately reflect the reporting person's ownership of the issuer's shares as of the current date.

Grant of restricted common stock vesting in three equal annual installments beginning November 10, 2026, subject to the achievement of performance criteria specified in the reporting person's award agreement.

Grant of restricted common stock vesting in three equal annual installments beginning November 10, 2026.

Grant of restricted common stock vesting in three equal annual installments beginning November 10, 2026.

Grant of restricted common stock vesting in three equal annual installments beginning November 10, 2026, subject to the achievement of performance criteria specified in the reporting person's award agreement.

Reflects purchases under the Company's ESPP plan which are not required to be reported on an ongoing basis. The purchases are being reported on this Form 4 to accurately reflect the reporting person's ownership of the issuer's shares as of the current date.

Grant of unrestricted common stock in lieu of cash director fees.

Grant of unrestricted common stock in lieu of cash director fees.

Grant of unrestricted common stock in lieu of cash director fees.

This transaction was executed in multiple trades at prices ranging from $34.0174 to $34.025. The price represents a weighted average price of the shares. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the shares purchased at each price.

Amount reflects purchases under the Company's ESPP plan which are not required to be reported on an ongoing basis. The purchases are being reported on this Form 4 to accurately reflect the reporting person's ownership of the issuer's shares as of the current date.